Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cyclobenzaprine extended release - Adare Pharmaceuticals

Drug Profile

Cyclobenzaprine extended release - Adare Pharmaceuticals

Alternative Names: Amrix; Bonelax; Bonelax ER; Cyclobenzaprine hydrochloride extended-release capsules; EUR-1002

Latest Information Update: 10 Apr 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eurand
  • Developer Adare Pharmaceuticals; Teva Pharmaceutical Industries
  • Class Anxiolytics; Dibenzocycloheptenes; Muscle relaxants; Small molecules
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Musculoskeletal pain; Spasm

Highest Development Phases

  • Marketed Musculoskeletal pain; Spasm
  • No development reported Migraine

Most Recent Events

  • 02 Apr 2015 Aptalis Pharmaceuticals has been acquired by TGP and renamed Adare Pharmaceuticals
  • 16 Mar 2015 Cyclobenzaprine extended release - Aptalis is available for licensing in Asia as of 16 Mar 2015. http://www.aptalispharmaceuticaltechnologies.com
  • 16 Mar 2015 No development reported - Phase-III for Migraine in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top